265 related articles for article (PubMed ID: 24930084)
1. [Vasoactive and inotropic drugs in acute heart failure].
Ruiz-Laiglesia FJ; Camafort-Babkowski M
Med Clin (Barc); 2014 Mar; 142 Suppl 1():49-54. PubMed ID: 24930084
[TBL] [Abstract][Full Text] [Related]
2. The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
Heywood JT; Khan TA
Rev Cardiovasc Med; 2007; 8 Suppl 5():S22-9. PubMed ID: 18192950
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of inodilators.
Dei Cas L; Metra M; Visioli O
J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S60-71. PubMed ID: 2483442
[TBL] [Abstract][Full Text] [Related]
4. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
Kubo SH
Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743
[No Abstract] [Full Text] [Related]
5. The role of intravenous vasodilators in acute heart failure management.
Piper S; McDonagh T
Eur J Heart Fail; 2014 Aug; 16(8):827-34. PubMed ID: 25100108
[TBL] [Abstract][Full Text] [Related]
6. Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
Chatterjee K; De Marco T
Med Clin North Am; 2003 Mar; 87(2):391-418. PubMed ID: 12693731
[TBL] [Abstract][Full Text] [Related]
7. The year in cardiology: heart failure 2014.
Voors AA; Ruschitzka F
Eur Heart J; 2015 Feb; 36(7):421-4. PubMed ID: 25575601
[No Abstract] [Full Text] [Related]
8. [New inotropic drugs].
Ferrari M; Cargnelli G; Piovan D; Bova S; Padrini R
G Ital Cardiol; 1982; 12(2):139-46. PubMed ID: 6293904
[No Abstract] [Full Text] [Related]
9. [Current role of non-digitalis inotropic agents in acute and chronic treatment of heart failure].
Dei Cas L; Nodari S; Raddino R; Metra M; Pelà G; Nardi M
Cardiologia; 1994 Mar; 39(3):209-15. PubMed ID: 8039201
[No Abstract] [Full Text] [Related]
10. Pharmacologic stabilization and management of acute heart failure syndromes in the emergency department.
Kirk JD; Parissis JT; Filippatos G
Heart Fail Clin; 2009 Jan; 5(1):43-54, vi. PubMed ID: 19026385
[TBL] [Abstract][Full Text] [Related]
11. Sympathomimetics, inotropics, and vasodilators.
Clements JV
AACN Clin Issues Crit Care Nurs; 1992 May; 3(2):395-408. PubMed ID: 1576037
[TBL] [Abstract][Full Text] [Related]
12. [Positive inotropic agents in heart failure. Clinico-pharmacological evidence for medical practice].
Rohde LE; Ribeiro JP
Arq Bras Cardiol; 1994 Dec; 63(6):537-42. PubMed ID: 7605243
[No Abstract] [Full Text] [Related]
13. An overview of inotropic agents.
Vroom MB
Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):246-52. PubMed ID: 16959760
[TBL] [Abstract][Full Text] [Related]
14. The failing heart and the hemodynamic response to vasodilator therapy.
Mills RM
Clin Cardiol; 2003 Jun; 26(6):257-8. PubMed ID: 12839041
[No Abstract] [Full Text] [Related]
15. Nesiritide (Natrecor): a new treatment for acutely decompensated congestive heart failure.
Colbert K; Greene MH
Crit Care Nurs Q; 2003; 26(1):40-4. PubMed ID: 12669946
[TBL] [Abstract][Full Text] [Related]
16. New drugs in the treatment of heart failure.
Brown L
Clin Exp Pharmacol Physiol; 1995 Nov; 22(11):829-32. PubMed ID: 8593738
[TBL] [Abstract][Full Text] [Related]
17. [Physiological bases and therapeutic uses of inodilator drugs].
Costa R; De Marino V; Marino A
Clin Ter; 1991 Jan; 136(2):85-94. PubMed ID: 1827377
[TBL] [Abstract][Full Text] [Related]
18. Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction.
Murtaza G; Siddiqui A; Hussain I
Curr Protein Pept Sci; 2018; 19(11):1079-1087. PubMed ID: 29984650
[TBL] [Abstract][Full Text] [Related]
19. New positive inotropic agents.
Jafri SM; Bristol JA
Henry Ford Hosp Med J; 1986; 34(3):188-92. PubMed ID: 3542907
[No Abstract] [Full Text] [Related]
20. Management of acute decompensated heart failure in an evidence-based era: what is the evidence behind the current standard of care?
Fares WH
Heart Lung; 2008; 37(3):173-8. PubMed ID: 18482628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
